Clinical Trials About "World Diabetes What Biotech Doing Fight Disease" RSS

09:06 EST 18th December 2018 | BioPortfolio

We list hundreds of Clinical Trials about "World Diabetes What Biotech Doing Fight Disease" on BioPortfolio. We draw our references from global clinical trials data listed on and refresh our database daily.

More Information about "World Diabetes What Biotech Doing Fight Disease" on BioPortfolio

We have published hundreds of World Diabetes What Biotech Doing Fight Disease news stories on BioPortfolio along with dozens of World Diabetes What Biotech Doing Fight Disease Clinical Trials and PubMed Articles about World Diabetes What Biotech Doing Fight Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of World Diabetes What Biotech Doing Fight Disease Companies in our database. You can also find out about relevant World Diabetes What Biotech Doing Fight Disease Drugs and Medications on this site too.

Showing "World Diabetes What Biotech Doing Fight Disease" Clinical Trials 1–25 of 24,000+


DISCOVER Global Registry

To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes and established micro- and/or macrovascular disease

Women in Control: A Virtual World Study of Diabetes Self-Management

This study evaluates the comparative effectiveness of a diabetes self management (DSM) group medical visit in the virtual world (Second life) verses a face-to-face format, aimed to increase physical activity and improve glucose control among Black/African American and Hispanic women with uncontrolled diabetes mellitus.

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Settings

DISCOVER is a Non Interventional Study study to describe the disease management patterns and clinical evolution over three years in type 2 diabetes mellitus patients initiating a second line anti-diabetic treatment.

DISCOVERing Treatment Reality of Type 2 Diabetes in Real World Setting in Japan

This study is intended to prospectively research the treatment reality and long-term disease control of Type 2 Diabetes Mellitus (T2DM) patients who are initiating 2nd line anti-diabetes treatment in sites across Japan.

Evaluation of the Impact of a Therapeutic Education Program for Children With Type 1 Diabetes

The needs of children and teens with type 1 diabetes are very specific and different from the adults with type 1 diabetes. Many organizations such as the World Health Organization or the International Society for Pediatric and Adolescent Diabetes, recommend a patient therapeutic education when it comes to children with type 1 diabetes. This study aims to evaluate the impact of a therapeutic education program on theoretical knowledge of the disease and also on quality of life, ...

Metabolic Characteristics of Lean Diabetes in Rural and Semi-urban India and in the United States

India has the world's highest prevalence of diabetes, expected to rise to 80 million by 2030. This includes many patients with lean diabetes, with low body mass index (BMI) and severe complications of diabetes. Despite its prevalence in India and other countries and its dire health consequences to individuals with the disease, little is known about the aetiopathogenesis and the genotype-phenotype relationship, lean diabetes being a cluster of low birth weight individuals, MODY,...

A Phase 3 Clinical Trial for a Rabies Vaccine (Vero Cell) for Human Use in Healthy Chinese Subjects

The purpose of this single-centre, randomized, double-blind, parallel control, phase 3 study is to evaluate the safety and immunogenicity of a rabies vaccine (Vero Cell) for human use in healthy Chinese subjects aged 10-60 years, according to the Essen methods (1-1-1-1-1) vaccination.

Health Outcomes of Patients With Type 2 Diabetes Treated With Dapagliflozin in Conjunction With Insulin

Real-world data can supplement the knowledge gained from traditional randomized controlled trials. To date, only a couple of studies (Andrew et al. 2014 and Wilding et al. 2015) have been conducted assessing the use of dapagliflozin in the real-world clinical settings in the United Kingdom and no research has been done on the use of dapagliflozin in Canadian clinical practice settings. To our knowledge, no real-world study exits assessing the impact of using dapagliflozin in ...

Low Fructose Diet in Diabetes Type 2

Diabetes is one of the most common and chronic diseases in the world, with the prevalence and incidence of this disease rising in most societies, especially in Iran. Suitable treatments for type 2 diabetes include changing lifestyle with exercise, nutrition, and drug use. New research suggests that added sugar, especially fructose, is the main trigger for diabetes and pre-diabetes even more potent than other carbohydrates. Fructose has a low glycemic index (23μg =) and slowly ...

Association of Angiotensin II Type 1 R Gene Polymorphism and Diabetic Nephropathy in Type 2 Diabetes

India is the "Diabetes Capital of the World" with 41 million Indians having diabetes, with every fifth diabetic in the world being an Indian and type 2 Diabetes Mellitus (T2DM) constitutes the major chunk of diabetes. One of the most severe complications of diabetes is the development of diabetic nephropathy. Diabetic nephropathy (DN) is the leading cause of end-stage renal disease (ESRD) worldwide. There are many identifiable risk factors of diabetic nephropathy like hyperglyc...

Pre-Competition Carbohydrate Supplementation

The objective of the present study was to evaluate the MPF and the perception of effort of professional jiu jitsu athletes from carbohydrate intake at different moments. Twelve jiu jitsu athletes participated in the study, being randomly divided into three groups of four participants: Control Group (CG); Experimental group 1 (G1), supplementation immediately before the fight and Experimental group 2 (G2), supplementation 30 minutes before the fight. The FPM measurement was perf...

Investigating the Safety and Effectiveness of Insulin Degludec in a Real World Population With Type 1 and 2 Diabetes Mellitus

This study is conducted in Europe. The aim of this non-interventional study is to investigate the safety and effectiveness of insulin degludec (Tresiba®) in a real world population with type 1 (T1DM) and 2 (T2DM) diabetes mellitus.

Quality of Life and Personality Traits in Patients With Type 1 Diabetes

The aims of this study are to examine the differences in the quality of life among individuals with type 1 diabetes and individuals without chronic diseases, differences in the quality of life among men and women with type 1 diabetes and the differences in the quality of life among individuals with good and poor glycaemic control. The relationship between personality traits and the management of disease in patients with type 1 diabetes will also be examined.

A Community-based Weight Loss Programme for Chinese Overweight Adults With Pre-diabetes

Type 2 diabetes (T2DM) is a serious chronic condition and one of the world's fastest growing health problems. The onset of T2DM is gradual, with most individuals progressing through a state of pre-diabetes. Pre-diabetes is a prevalent and potentially reversible condition, which provides an important window of opportunity for the prevention of T2DM and its complications. This project aims to translate the evidence-based diabetes prevention strategies into a community setting to ...

Cyber Disease Management: Using the World Wide Web to Share the Medical Record With Patients at Home

This is a 12-month randomized, controlled trial of a Web-based diabetes co-management module among type 2 patients at the University of Washington's Roosevelt General Internal Medicine Clinic.

Phase I Hepatitis C Vaccine Trial of Virosome-formulated Peptides

Pevion Biotech has designed a therapeutic vaccine to treat patients who suffer from chronic hepatitis C virus infection. The vaccine is based on a combination of the PeviPRO and PeviTER platforms using synthetic peptide antigens from the hepatitis C virus. Generally, a cellular immune response by cytotoxic T-lymphocytes (CTL) seems to be crucial in overcoming a hepatitis C virus infection. In-depth research in recent years has shown that the cellular immune response is even mor...

EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)

Type 1 diabetes (T1D) results from destruction of insulin-producing beta cells in the pancreas by the body's own immune system (autoimmunity). We do not fully understand what causes this type of diabetes and why there is variation in age of onset and severity between people who develop the disease. The aim of this work is to study very unusual people who develop T1D extremely young, as babies under 1 year of age. We think that, for the condition to have developed that early, th...

Real World Experience of Dapaglifozin in Type 2 Diabetes

Type 2 diabetes is creating a health pandemic globally. Management of type 2 diabetes involves combination of lifestyle intervention and drug intervention, which includes sodium-glucose transporter 2 (SGLT-2) inhibitors, such as dapagliflozin. Dapagliflozin (Forxiga®) was approved by the Malaysian Drug Authority for the treatment of type 2 diabetes in 2014. This study will describe the characteristics of patients who are prescribed dapagliflozin by diabetologists/endocrinologi...

A Study of the Effectiveness of Xultophy® (Insulin Degludec/Liraglutide) in an Adult Real-world Population With Type 2 Diabetes Mellitus

This study is conducted in Europe. The aim of this study is to investigate the effectiveness of Xultophy® (insulin degludec/liraglutide) in an adult real-world population with type 2 diabetes mellitus.

Chongqing Diabetes Registry

To investigate the risk factors and biomarkers of the microvascular disease,macrovascular disease and neuropathy in patients with diabetes.

Oral Insulin for Prevention of Diabetes in Relatives at Risk for Type 1 Diabetes Mellitus

Type 1 diabetes (T1D) is an autoimmune disease. This means that the immune system (the part of the body which helps fight infections) mistakenly attacks and destroys the cells that produce insulin (islet cells found in the pancreas). As these cells are destroyed, the body's ability to produce insulin decreases. There is evidence suggesting that repeated oral administration of an autoantigen (the same protein that the immune system is reacting to) may introduce a protective immu...

DAPA-Egypt (Non Interventional Study)

Approximately 39 million people of adults aged 20-79 are living with Diabetes in MENA region in 2017, Egypt is number 8 in the top 10 countries in number of adults with Diabetes (8.2 million), where Egypt represents 21% of the Diabetics in MENA region. Metformin is used as 1st line oral anti-diabetic drug in most cases. Sulfonylureas (SU) are used as frequent first add-on after failure of metformin monotherapy. Sodium Glucose Co-transporter 2 (SGLT2) inhibitors are a newer cla...

Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies

India is the "Diabetes Capital of the World" with 41 million Indians having diabetes i.e. every fifth diabetic in the world is an Indian1. Type 2 Diabetes Mellitus (T2DM) constitutes the major chunk of diabetes and has insulin resistance as the hallmark feature in the pathogenesis. However, with the progression of the disease the insulin resistance becomes stable whereas β - cell function shows a gradual decline due to its ongoing apoptosis2. This ultimately leads to inability...

Aflibercept for Retinopathy in the Real World

Diabetic retinopathy remains the leading cause of blindness in patients of working age in the Western World, and there is a global epidemic of diabetes. The recommended treatment for diabetic retinopathy involves injection of anti-vascular endothelial growth factor (anti-VEGF) into the eye. Based on two recent clinical trials taking place in the United States, Europe, Japan, and Australia, NICE issued guidance in July 2015 recommending that aflibercept (a particular type of ant...

Mobile Technology & Online Tools to Track Adherence in Chronic Illness Patients

The purpose of this project is to test the efficacy of Planet T1D, a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedba...

More From BioPortfolio on "World Diabetes What Biotech Doing Fight Disease"

Quick Search